Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

Table 4

Comparison of clinical background between the effective group and ineffective group in obese subjects with type 2 diabetes (BMI ≥ 25 kg/m²).

Clinical parameter	Effective group	Ineffective group	value
Number	58	30
Gender (men/women); n (%)	34 (59)/24 (41)	18 (60)/12 (40)	N.S.
Age (year)	60.9 ± 10.5	51.8 ± 12.8	0.0008
BMI (kg/m^2)	29.6 ± 4.9	29.4 ± 4.8	N.S.
Duration of diabetes (year)	12.7 ± 8.3	11.3 ± 6.9	N.S.
Family history of diabetes (%)	51	55	N.S.
Baseline HbA1c (%) (mmol/mol)	8.0 ± 1.6	7.8 ± 1.2	N.S.
	64 ± 17.5	62 ± 13.1
Body weight change (kg)	0.5 ± 5.7	0.7 ± 4.3	N.S.
Total cholesterol (mg/dl)
Baseline	185 ± 35	196 ± 35	N.S.
Average over 1 year	177 ± 23	190 ± 29	0.04
Triglyceride (mg/dl)
Baseline	139 ± 70	202 ± 127	0.02
Average over 1 year	137 ± 49	209 ± 120	0.005
HDL cholesterol (mg/dl)
Baseline	53 ± 12	50 ± 12	N.S.
Average over 1 year	52 ± 11	50 ± 11	N.S.
LDL cholesterol (mg/dl)
Baseline	103 ± 31	110 ± 30	N.S.
Average over 1 year	98 ± 19	106 ± 24	N.S.

BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein; N.S.: not significant. Data are described as mean ± SD.